Tiny particles called quantum dots reduce symptoms in mice primed to develop a type of Parkinson’s disease, and also block formation of the toxic protein clumps in Alzheimer’s. They could one day be a novel treatment for these brain disorders, although tests in people are some years away.
Quantum dots are just a few nanometres in size – so small they become subject to some of the strange effects of quantum physics. They have useful electronic and fluorescent properties and are found in some TV screens and LED lights.
Unlike most medicines, their tiny size means they can pass from bloodstream into the brain. Byung Hee Hong of Seoul National University in the South Korea and his colleagues wondered if they would affect the molecules involved in Parkinson’s or other brain disorders.
Parkinson’s disease involves gradually worsening tremors and movement problems. It is thought to be caused by a protein called synuclein found in nerve cells folding into the wrong shape, which triggers a chain reaction of misfolding in nearby synuclein molecules. This leads to a build-up of long strands or “fibrils” of the protein, killing neurons.
Hong’s team found that in a dish, quantum dots made from graphene – a form of carbon – bind to synuclein, and not only stop it from clumping into fibres, but also cause existing fibres to break up into individual molecules. “We didn’t expect the quantum dots to induce disaggregation of fibrils,” says Hong.
If the treatment affects people the same way, Hong says it is unclear how much benefit this would bring. “It’s hard to translate the results in mice to actual patients, whose systems are way more complicated. But we do believe quantum dots can make positive impacts to some extent.”
Image Credit: May C. Schiess, Roger Back, UT Medical School/Science Photo Library
News This Week
Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble [...]
A technology developed at Vanderbilt University Medical Center has led to the discovery of an "ultra-potent" monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. The antibody [...]
Research has found a significant fall in levels of antibodies against SARS-CoV-2, the virus that causes COVID-19, 6 months after the second dose of the Pfizer-BioNTech vaccine. Clinical evidence also suggests that the risk [...]
Are the COVID vaccines substantially different from/inferior to other vaccines in terms of their effectiveness? The issue raised, and I'm mostly paraphrasing here, is this: Most vaccines (e.g. measles, smallpox) have efficacy defined such [...]
The EVONANO platform allows scientists to grow virtual tumors and use artificial intelligence to automatically optimize the design of nanoparticles to treat them. The ability to grow and treat virtual tumors is an [...]
Modern Approaches to Augmentation of Brain Function Available from Springer Press This book covers recent advances in neural technology that provide for enhancements for brain function. It addresses a broad range of neural phenomena [...]
Although the currently available COVID-19 vaccines are highly effective, limited manufacturing capacity and the need for cold-chain storage hinder their global distribution. A recent study tested the efficacy of a new adeno-associated virus (AAV) [...]